Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

FOSTER CITY, Calif., June 12, 2026--(BUSINESS WIRE)--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company's long-standing work to address emerging infectious diseases.

"At Gilead, we recognize the urgency and human toll of global health emergencies – and the responsibility to act quickly," said Anu Osinusi, MD, Vice President, Clinical Development, Virology at Gilead Sciences. "Building on decades of experience responding to serious infectious diseases, our teams are working alongside partners with focus and purpose to support the response to this outbreak."

Remdesivir is being provided to support the Ugandan Ebola outbreak under both compassionate use and Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) frameworks for the treatment of BVD. In parallel, Gilead is preparing to support requests from the Democratic Republic of the Congo, World Health Organization (WHO) and other regional and global partners for both remdesivir and obeldesivir, an oral investigational antiviral agent, as part of the broader regional response to Ebola BVD, including the support of several planned clinical trials.

Over the past decade, Gilead has aided responses to multiple filovirus outbreaks in Sub-Saharan Africa through donation of remdesivir for emergency and compassionate use, as well as for investigational use in clinical trials – reflecting a sustained commitment to rapid response in times of urgent need.

Remdesivir has demonstrated promising preclinical activity across multiple filoviruses but has not been approved for the treatment of filovirus disease in any country. The safety and efficacy of remdesivir for the Bundibugyo strain have not yet been established; ongoing studies are working to generate this evidence.

About Remdesivir

Remdesivir is a nucleotide analog prodrug invented and developed by Gilead, building on more than a decade of the company's antiviral research. Remdesivir has broad-spectrum antiviral activity both in vitro and in animal models against multiple viral pathogens, including Marburg, Ebola, SARS, MERS and SARS-CoV-2, the virus that causes COVID-19.

Remdesivir has been approved as a COVID-19 treatment in approximately 50 countries worldwide. To date, remdesivir has been made available to more than 14.5 million patients around the world, including more than 8.1 million people in middle- and low-income countries through Gilead's voluntary licensing program.

Story Continues

The clinical efficacy of remdesivir for BVD remains to be established. Remdesivir is currently not approved in any country for the treatment of BVD. This emergency use donation is based on the preclinical data for Ebola virus together with extensive clinical safety data from the use of remdesivir for the treatment of COVID-19.

For more information about Gilead's commitment to global health, visit Gilead.com.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611120432/en/

Contacts

Ashleigh Koss, Media Public_Affairs@gilead.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy endpoint at Week 48 in both studies, showing statistical non-inferiority when compared to daily standard-of-care antiretroviral therapies.

This novel combination uses two distinct mechanisms of action: islatravir, a next-generation nucleoside analog, and lenacapavir, a first-in-class capsid inhibitor that disrupts the HIV lifecycle at multiple stages. The companies reported that the safety profile of the once-weekly tablet was generally comparable to existing treatments, with no new safety concerns identified throughout the trials.Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?

If approved, the regimen would become the first long-acting oral HIV treatment taken only once per week, offering patients increased flexibility and discretion. Gilead Sciences Inc. (NASDAQ:GILD) and Merck plan to submit these Phase 3 findings to global regulatory authorities and present detailed data at an upcoming scientific congress to further support the development of this potential new standard of care.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Mergers and acquisitions (M&A) activity across pharmaceutical and biotech sectors has accelerated significantly in 2026, extending the strong recovery that began in 2025.

A recent surge in dealmaking underscores the industry's focus on portfolio expansion and continuous pipeline innovation, alongside a growing emphasis on AI-driven drug discovery. Oncology and immuno-oncology companies have always been at the top of acquisition targets. Major players are actively pursuing licensing agreements and collaborations around promising drugs and candidates to further strengthen and diversify their core portfolios.

Quick Take on Recent M&A Deals

Pharma conglomerate Johnson & Johnson recently announced that it will acquire Firefly Bio for $1 billion and gain access to its Firelink degrader antibody conjugate platform. The deal strengthens Johnson & Johnson's oncology pipeline by adding a targeted approach for KRAS-driven cancers, supporting its efforts to develop treatments for some of the most common and challenging solid tumors.

Other pharma giants Eli Lilly LLY and Novartis NVS have been on an acquisition spree this year.

Lilly recently announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company, expanding its infectious disease research and development capabilities.

Lilly has been actively expanding its pipeline through acquisitions. LLY is all set to acquire Ajax Therapeutics, which will add AJ1-11095, a potential first-in-class oral type II JAK2 inhibitor currently in phase I testing for myelofibrosis patients previously treated with type I JAK2 inhibitors, to its pipeline.  The company also announced a deal to acquire clinical-stage biotechnology company Kelonia Therapeutics, Inc, a pioneer in vivo gene delivery.

The company had earlier agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, which will add orexin-based sleep disorder candidate cleminorexton to its pipeline. Lilly also struck a deal worth up to $2.4 billion for Orna Therapeutics, to gain access to its circular RNA-based immune cell engineering platform. Lilly also acquired Ventyx Biosciences to strengthen its portfolio of oral therapies targeting inflammatory diseases.

Swiss pharma bigwig Novartis, too, has been very active on the M&A front.  NVS is set to acquire Excellergy Inc., strengthening its immunology pipeline with a focus on food allergies and other IgE-mediated conditions. The deal brings in EXL-111, a phase I, half-life-extended anti-IgE antibody.

Earlier this year, Novartis acquired Avidity Biosciences, adding its antibody oligonucleotide conjugate (AOC) platform and three late-stage programs, further bolstering its neuromuscular pipeline.

Story Continues

Last month, Merck MRK acquired Terns Pharmaceuticals for $53 per share in cash. The deal adds TERN-701, a potential best-in-class treatment for chronic myeloid leukemia that recently received FDA Breakthrough Therapy Designation. The acquisition strengthens Merck's oncology pipeline.

Among biotech giants, Gilead Sciences, Inc. GILD is ramping up its external innovation strategy through targeted acquisitions to strengthen its pipeline and reduce reliance on its core HIV franchise.

Gilead and partner Lakefront Biotherapeutics (formerly known as Galapagos) recently acquired Ouro Medicines, adding gamgertamig, a clinical-stage BCMAxCD3 T-cell engager, to strengthen their autoimmune disease and inflammation pipeline.

Last month, Gilead acquired Tubulis, a clinical-stage biotech focused on developing next-generation antibody-drug conjugates (ADCs), strengthening its oncology pipeline.

Earlier this year, GILD acquired Arcellx for about $7.8 billion. The acquisition gives Gilead full ownership of anito-cel, an investigational late-stage CAR-T therapy for multiple myeloma with a potential U.S. decision by December 2026.

Another biotech giant Biogen recently acquired Apellis Pharmaceuticals $41 per share in cash plus contingent value rights worth up to an additional $4 per share tied to future sales milestones. The acquisition adds two commercialized therapies, Empaveli and Syfovre, to Biogen's portfolio. Together, the drugs generated $689 million in sales in 2025. The transaction strengthens Biogen's presence in immunology and rare diseases while establishing a foothold in nephrology.

Earlier this week, GSK plc GSK announced that it will acquire clinical-stage biopharmaceutical company Nuvalent for $10.6 billion, gaining three lung cancer assets, including late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib, both under FDA review. The deal strengthens GSK's oncology pipeline, expands its presence in lung cancer, and is expected to contribute to sales and operating profit growth beginning in 2027.

GSK earlier acquired RAPT Therapeutics to strengthen its immunology pipeline. The company also bought 35Pharma, adding HS235, a potential best-in-class therapy for pulmonary hypertension.

Last week, Servier (an independent international pharmaceutical group governed by a foundation) agreed to acquire the muscular dystrophy business of Edgewise Therapeutics in a deal worth up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestone payments.

Road Ahead in 2026

Consolidation remains a key theme as companies seek to offset patent cliffs and diversify revenue streams. Acquisitions offer a faster, less risky route than in-house development, especially as innovation cycles shorten.

With strong cash reserves and increasing adoption of advanced technologies like AI, M&A activity is expected to remain robust through 2026. Smaller biotechs, often constrained by funding, will likely remain prime acquisition targets, further fueling deal momentum.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report

Novartis AG (NVS) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

[Metallic 3d Number Ten On Smooth Blue Surface With Soft Reflection] sankai/iStock via Getty Images

Wall Street’s recent pullback has pushed a growing number of S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) constituents into oversold territory, highlighting areas of the market that have experienced some of the sharpest selling pressure since the benchmark index peaked at a record 7,620.

The S&P 500 has declined approximately 4.6% from its high, falling to around 7,265 as investors navigated a period of heightened volatility and broad-based weakness across equities. The retreat has weighed heavily on several individual stocks, driving technical indicators to levels often associated with stretched downside momentum.

One of the most closely watched measures of market sentiment, the relative strength index, suggests that a number of large-cap names have become deeply oversold. An RSI reading below 30 is commonly viewed by technical analysts as a signal that selling pressure may have become excessive.

Among the S&P 500 stocks showing the weakest momentum, Trimble (TRMB [https://seekingalpha.com/symbol/TRMB]) currently ranks as the most oversold member of the S&P 500, posting an RSI reading of 25.85.

Outlined below are the top 10 most oversold names in the benchmark index:

* Trimble (TRMB [https://seekingalpha.com/symbol/TRMB]) — RSI 25.85
* PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) — RSI 27.16 
* Mosaic (MOS [https://seekingalpha.com/symbol/MOS]) — RSI 27.29
* Tyson Foods (TSN [https://seekingalpha.com/symbol/TSN]) — RSI 28.02 
* Albemarle (ALB [https://seekingalpha.com/symbol/ALB]) — RSI 28.30
* Gilead Sciences (GILD [https://seekingalpha.com/symbol/GILD]) — RSI 29.25
* Jack Henry & Associates (JKHY [https://seekingalpha.com/symbol/JKHY]) — RSI 29.34
* GE Vernova (GEV [https://seekingalpha.com/symbol/GEV]) — RSI 29.35 
* Global Payments (GPN [https://seekingalpha.com/symbol/GPN]) — RSI 29.47
* Corteva (CTVA [https://seekingalpha.com/symbol/CTVA]) — RSI 29.59 

S&P 500 FUNDS: (SPY [https://seekingalpha.com/symbol/SPY]), (VOO [https://seekingalpha.com/symbol/VOO]), (IVV [https://seekingalpha.com/symbol/IVV]), (RSP [https://seekingalpha.com/symbol/RSP]), (SSO [https://seekingalpha.com/symbol/SSO]), (UPRO [https://seekingalpha.com/symbol/UPRO]), (SH [https://seekingalpha.com/symbol/SH]), (SDS [https://seekingalpha.com/symbol/SDS]), (SPXU [https://seekingalpha.com/symbol/SPXU]), (FXAIX [https://seekingalpha.com/symbol/FXAIX]), (VFIAX [https://seekingalpha.com/symbol/VFIAX]), (VFFSX [https://seekingalpha.com/symbol/VFFSX]), and (SWPPX [https://seekingalpha.com/symbol/SWPPX]).

MORE ON MARKETS

* Over 40% of S&P 500 stocks trade below their 200-day MA amid selloff [https://seekingalpha.com/news/4602308-over-40-of-sp-500-stocks-trade-below-their-200-day-ma-amid-selloff]
* Market pullback is viewed as a healthy pause, Morgan Stanley says [https://seekingalpha.com/news/4602221-market-pullback-is-viewed-as-a-healthy-pause-morgan-stanley-says]
* 15 dividend stocks to watch as downward momentum grips Wall Street [https://seekingalpha.com/news/4602204-15-dividend-stocks-to-watch-as-downward-momentum-grips-wall-street]
* Gold sinks to its lowest recorded level since November [https://seekingalpha.com/news/4602152-gold-sinks-to-its-lowest-recorded-level-since-november]
* Silver falls below 200-day MA, down 45% from its record high set earlier this year [https://seekingalpha.com/news/4601860-silver-falls-below-200-day-ma-down-45-percent-from-its-record-high-set-earlier-this-year]

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Daniel O’Day, Chairman and CEO, Gilead Sciences, speaking at the National AIDS Memorial Grove in San Francisco for World AIDS Day.

• Three-year, ~$3M commitment to expand leadership development, strengthen HIV education and engagement, and preserve the HIV movement’s history for future generations -

SAN FRANCISCO & FOSTER CITY, Calif., June 11, 2026--(BUSINESS WIRE)--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight against HIV/AIDS has always depended on more than medicine. It has required scientific innovation, public education, activism, compassion, communities caring for one another through crisis and change, and a shared commitment to ensuring these stories are never lost.

The initiative will help expand leadership development for emerging advocates, increase access to the stories preserved within the AIDS Memorial Quilt, elevate community voices through public engagement programs, and support stewardship of the National AIDS Memorial Grove.

"The history of the HIV movement is defined by acts of courage, activism, compassion, and community leadership. Through the Gilead Foundation’s partnership with the National AIDS Memorial, we are helping ensure those stories and experiences continue to educate future generations and inspire them to make their own contributions," said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. "As science transforms what is possible in the fight against HIV, the hard-won lessons of this movement must continue to guide how we advance innovation, expand access, and support the communities most affected."

For the National AIDS Memorial and the Gilead Foundation, that commitment reflects a shared belief that remembrance is not simply about preserving history but helping shape what comes next.

"The work of remembrance is future work," said John Cunningham, Chief Executive Officer of the National AIDS Memorial. "This transformative commitment allows us not only to care for the Quilt and Grove entrusted to us, but to ensure that the stories and enduring lessons of the HIV/AIDS movement remain active forces in public life. We want future generations to understand not only the history of the epidemic, but the determination that shaped the response, and to recognize their own power to carry that work forward."

The commitment will expand the Pedro Zamora Young Leaders Scholarship and Fellowship Program, creating new opportunities for emerging leaders pursuing careers in public health, medicine, education, social justice, and HIV advocacy. It will also support a multi-year effort to preserve and re-digitize thousands of AIDS Memorial Quilt panels, making them more accessible to families, educators, students, researchers, and communities worldwide.

Story Continues

The initiative will expand public programs that encourage dialogue on leadership, community engagement, and the ongoing HIV response, including the National AIDS Memorial Leadership Award and Speaker Series. Funding will also support conservation efforts, volunteer programs, and future enhancements at the National AIDS Memorial Grove in San Francisco’s Golden Gate Park, a place of reflection, healing, and community connection.

The initiative builds on years of collaboration between the National AIDS Memorial and the Gilead Foundation, including support for Quilt preservation, public education initiatives, and programs reaching communities disproportionately impacted by HIV. The commitment arrives at a milestone moment for the HIV community: this year the Grove marks its 35th anniversary, and in 2027 the Quilt will reach its 40th. Together they stand as national symbols of remembrance, resilience and community action.

Funding will also support future chapters of Surviving Voices, the National AIDS Memorial’s award-winning documentary series preserving oral histories from people and communities affected by HIV. Alongside expanded Quilt access, leadership programs, and community engagement initiatives, these efforts will help ensure the experiences and contributions of those impacted by the epidemic remain visible and accessible for future generations.

Today, the AIDS Memorial Quilt remains the world’s largest community folk art project, with more than 50,000 panels honoring more than 110,000 lives. Together with the Grove, these living memorials continue to serve as places of remembrance and resources for education, connection, and engagement.

As the HIV community looks ahead, the National AIDS Memorial and the Gilead Foundation remain committed to ensuring that the history, voices, and lessons that shaped the response to HIV continue to inspire progress toward a healthier future for all.

About the National AIDS Memorial

The National AIDS Memorial stewards the National AIDS Memorial Grove and the AIDS Memorial Quilt to remember, heal, and inspire—and to ensure the ongoing story and lessons of the AIDS crisis foster a more just, healthy society.

About the Gilead Foundation

The Gilead Foundation is a nonprofit organization that works to create a thriving health ecosystem. The Gilead Foundation takes a holistic approach to mitigate the root causes of health inequities by providing resources to organizations that empower people with the skills to be their own best advocate and create systems of support that strengthen communities, classrooms and workplaces.

About Gilead Sciences

Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611344912/en/

Contacts

Gilead Contacts: Elizabeth Baxter, Media public_affairs@gilead.com

Jacquie Ross, Investors investor_relations@gilead.com

National AIDS Memorial Contact: Mike Fung, Media mfung@aidsmemorial.org

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention.

Last month, the company reported better-than-expected first-quarter results, driven by strong HIV breast cancer drug Trodelvy and liver disease drug Livdelzi sales.

HIV business continues to maintain momentum, driven by solid performance of Biktarvy and Descovy, and incremental contributions from Yeztugo.

Biktarvy continues to be a dominant player in the HIV treatment market, holding more than 52% market share and retaining its position as the most prescribed therapy for both treatment-naïve and switch patients across major markets.

Gilead's HIV pre-exposure prophylaxis (PrEP) portfolio comprises daily oral Descovy and the first and only twice-yearly injectable Yeztugo.

Descovy's performance continues to be strong, primarily driven by higher demand and average realized price.

The FDA approval of injectable lenacapavir, a first-in-class capsid inhibitor (under the brand name Yeztugo), solidifies GILD's HIV portfolio. With a twice-yearly dosing schedule, the therapy offers meaningful adherence advantages over daily oral regimens and targets a broad patient population.

Following better-than-expected first-quarter results and improving market trends, Gilead raised its 2026 sales guidance for Yeztugo to $1 billion, signaling the product's potential to achieve blockbuster status in its first full year on the market.

Driven by increased Yeztugo sales expectations and strong first-quarter HIV performance, Gilead now projects total 2026 HIV sales growth of approximately 8% year over year, up from its prior guidance of 6% issued in February. The updated outlook includes an estimated 2% headwind related to the U.S. government's Medicaid drug pricing agreement and proposed Affordable Care Act changes.

The FDA accepted Gilead's new drug application for bictegravir/lenacapavir (BIC/LEN) for virologically suppressed people living with HIV under priority review, setting a target action date of Aug. 27, 2026.  A potential approval of BIC/LEN will further bolster its HIV portfolio.

Looking ahead, with no significant loss-of-exclusivity (LOE) events expected until 2036, Gilead's HIV franchise is well positioned for sustained long-term growth, supported by the potential launch of up to seven new HIV therapies by 2033.

GILD has also collaborated with Merck MRK to advance its HIV pipeline further.

Gilead and Merck recently announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, evaluating investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir.

Story Continues

The investigational regimen combines Merck's islatravir, a next-generation nucleoside analog that inhibits HIV replication through multiple mechanisms, including reverse transcriptase translocation inhibition, with Gilead's lenacapavir.

Both studies met the primary efficacy endpoint at week 48. Following the positive phase III results, Gilead and Merck intend to submit the ISLEND trial data to regulatory authorities worldwide and present detailed study findings at an upcoming scientific conference.

Gilead presented encouraging phase I data for the long-acting integrase inhibitor GS-3242 in February. Additional data expected later this year could support the development of a twice-yearly injectable regimen combining GS-3242 with lenacapavir.

Approval of additional treatments should strengthen its dominant HIV franchise.

Competition for GILD's HIV Business

The HIV treatment landscape is dominated by many bigwigs, such as GSK plc GSK and Merck, apart from GILD.

HIV sales account for a major chunk of GSK's Specialty Medicines portfolio. GSK continues to grow its HIV business, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato. The solid growth from these drugs has helped GSK combat the decline in Triumeq sales.

MRK markets doravirine for treating adults with HIV-1 in the United States, either as a monotherapy under the brand name Pifeltro or as part of the single-tablet combination regimen under the brand name Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate).

MRK recently won FDA approval of Idvynso, a once-daily, two-drug single-tablet regimen containing doravirine (100 mg) and islatravir (0.25 mg), for adults living with HIV-1 who are virologically suppressed on a stable antiretroviral regimen. The approval covers patients with no history of treatment failure and no known resistance-associated mutations to doravirine, allowing them to switch from their current HIV therapy.

Merck is also evaluating a once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in treatment-naïve adults with HIV-1 infection.

GILD's Price Performance, Valuation and Estimates

Shares of GILD have gained 2.3% year to date against the industry's decline of 3.1%.Zacks Investment Research

Image Source: Zacks Investment Research

Going by the price/earnings ratio, GILD's shares currently trade at 33.39X forward earnings, higher than its mean of 11.87X and the large-cap pharma industry's 17.59X.Zacks Investment Research

Image Source: Zacks Investment Research

The consensus estimate for 2026 has deteriorated sharply over the past 30 days, shifting to a loss of 79 cents per share from projected earnings of $4.32 per share. The estimate for 2027 has also edged lower to $9.53 per share from $9.57 during the same period.Zacks Investment Research

Image Source: Zacks Investment Research

While Gilead's recent aggressive dealmaking strategy strengthens its long-term pipeline and growth potential, the sizable upfront payments and integration-related costs are pressuring near-term profitability.

GILD currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments.

Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with returns up 5.6% over the past week and 7.1% over the past 30 days, while the year-to-date move shows a decline of 17.5%. Over longer periods, returns of 59.6% over 3 years and 147.3% over 5 years show how much the stock has moved over time.

For investors tracking NYSE:COR, this partnership highlights Cencora’s role in the growing area of complex therapies and specialized distribution. The deal may influence how the market views Cencora’s position in next generation treatment logistics and its relationships with large biopharma partners.

Stay updated on the most important news stories for Cencora by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Cencora.NYSE:COR Earnings & Revenue Growth as at Jun 2026

5 things going right for Cencora that this headline doesn't cover.

Investor Checklist

Quick Assessment

✅ Price vs Analyst Target: At US$279.57, the stock sits about 25% below the US$350.58 analyst consensus target. ✅ Simply Wall St Valuation: Shares are flagged as undervalued, trading 42.6% below the platform's estimated fair value. ✅ Recent Momentum: The price is up 7.1% over the past 30 days, showing short term strength as this Kite deal lands.

There's only one way to know the right time to buy, sell or hold Cencora. Head to Simply Wall St's company report for the latest analysis of Cencora's Fair Value.

Key Considerations

📊 The Kite CAR T partnership reinforces Cencora’s role in complex therapy distribution. This may be important for how investors view its long term business mix. 📊 Keep an eye on CAR T treatment volumes, new center activations, and any disclosure on revenue tied to cell and gene therapy logistics. ⚠️ The main flagged risk is that debt is not well covered by operating cash flow. Investors may want to watch leverage and cash generation as capital needs evolve.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Cencora analysis. Alternatively, you can check out the community page for Cencora to see how other investors believe this latest news will impact the company's narrative.

Story Continues

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include COR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) hat heute den Start eines Aktienrückkaufprogramms (das "Programm") angekündigt, unter dem die Gesellschaft bis zu €50 Millionen an Aktien zurückkaufen kann. Der Rückkauf soll innerhalb von 12 Monaten abgeschlossen sein und wird mit Morgan Stanley & Co International PLC durchgeführt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Gilead Sciences, Inc. (GILD) und ihr Partner Merck (MRK) haben positive Daten aus zwei spätstadiellen Studien, ISLEND-1 und ISLEND-2, vorgestellt. Diese Studien evaluierten die investigativen oralen einmal-wöchentlichen Ein-Tages-HIV-Therapie-Regime von Islatravir/Lenacapavir.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Aktie von Gilead Sciences (NasdaqGS:GILD) notiert bei $128,1. Das Unternehmen hat im vergangenen Jahr einen Anstieg von 16,4% verzeichnet und ist innerhalb der letzten fünf Jahre um mehr als das Doppelte gestiegen. Die erfolgreiche HIV-Studie hebt den potenziellen Fortschritt in lang anhaltenden Behandlungen hervor. Im Gegensatz dazu wirft die Rückschlag im Lungenkrebs eine Frage über die Geschwindigkeit und Form von Gileads Onkologie-Bemühungen auf.